Mydecine Innovation's Mindleap subsidary launches a telehealth platform for psychedelics.
Exploring the companies and themes that make up this emerging and exciting new sector
Why Is Kevin O’Leary So Bullish On Psychedelics?
Kevin O’Leary won’t touch cannabis as an investment but he loves the potential of psychedelic drugs. Why?
The Three Hottest Psychedelic Stocks That Every Investor Should Research
Psychedelic stocks have exploded on news of the Compass Pathways IPO. Three companies are leading the charge.
MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin
New research initiative will compare the efficacy of psilocybin with LSD.
Why Are Silicon Valley Billionaires Unicorn-Hunting In Psychedelics?
Move over Big Pharma, Here Comes Silicon Valley Investment In Psychedelics Stocks Like Compass Pathways (CMPS)
Why Is Silicon Valley Unicorn-Hunting In Big Pharma's Backyard?
Move over Big Pharma, Here Comes Silicon Valley Investment In Psychedelics Stocks Like Compass Pathways (CMPS)
Health Canada Authorization to Sell its Moonbeam Mushroom Products in Canada
Mind Cure's organic Moonbeam mushroom products are now eligible for sale in Canada.
Mind Cure Receives Health Canada Authorization to Sell its Moonbeam Mushroom Products in Canada
Mind Cure's organic Moonbeam mushroom products are now eligible for sale in Canada.
COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
Compass Pathways has closed its IPO financing, raising $146.6 million via the sale of 8,625,000 American Depository Shares.
Psychedelics Stock Warrants Offer Interesting Leverage Play
Psychedelic stock warrants that are currently out of the money COULD produce big returns for investors.
PharmaDrug Inc. Closes Transaction to Acquire First Smart Shop in the Netherlands, Initiates Major Push to Acquire Best of Breed High Traffic Locations
PharmaDrug will assume control of its first Super Smart psychedelics store on October 1st.
MindMed Catches Fire, Seeks To Up-List On NASDAQ
MindMed stock has spiked higher by over 30%, on big volume. New investor focus on the deepest clinical research program in the industry.